Phathom Pharmaceuticals (PHAT) Receivables (2023 - 2025)
Historic Receivables for Phathom Pharmaceuticals (PHAT) over the last 3 years, with Q3 2025 value amounting to $55.8 million.
- Phathom Pharmaceuticals' Receivables rose 16500.57% to $55.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $55.8 million, marking a year-over-year increase of 16500.57%. This contributed to the annual value of $38.8 million for FY2024, which is 227000.61% up from last year.
- According to the latest figures from Q3 2025, Phathom Pharmaceuticals' Receivables is $55.8 million, which was up 16500.57% from $51.3 million recorded in Q2 2025.
- Phathom Pharmaceuticals' 5-year Receivables high stood at $55.8 million for Q3 2025, and its period low was $1.6 million during Q4 2023.
- Moreover, its 3-year median value for Receivables was $28.7 million (2024), whereas its average is $27.5 million.
- As far as peak fluctuations go, Phathom Pharmaceuticals' Receivables skyrocketed by 227000.61% in 2024, and later soared by 16500.57% in 2025.
- Over the past 3 years, Phathom Pharmaceuticals' Receivables (Quarter) stood at $1.6 million in 2023, then surged by 2270.01% to $38.8 million in 2024, then soared by 43.8% to $55.8 million in 2025.
- Its Receivables stands at $55.8 million for Q3 2025, versus $51.3 million for Q2 2025 and $36.4 million for Q1 2025.